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Background: Dermatophytosis is a common fungal dis-
ease which affected derma and their appendages. Many
antifungal drugs prescribe ordinary against dermatophyto-
sis every day and there are many reports concerning on
failure in treatment of dermatophytosis. Antifungal suscep-
tibility testing is a very dynamic ﬁeld of medical mycology.
In this study, antifungal activities of six antifungal agents
were evaluated against clinically isolated of dermatophytes
in Shiraz, Southern Iran.
Method: Forty clinical dermatophytes were isolated
and identiﬁed from patients suspected of dermatophyto-
sis referred to the mycology laboratory of Shiraz Medical
School. Home made antifungal disks were prepared from
standard powders of terbinaﬁne, griseofulvin, clotrimazole,
miconazole, ﬂuconazole and Ketoconazole. Antifungal sus-
ceptibility test performed by disk diffusion method and the
mean diameter of the inhibition zones around the disks were
measured and compared with the disk controls.
Results: The isolates belong to three genera and eight
species as Trichophyton mentagrophytes (13) Trichophyton
rubrum(8), Epidermophyton ﬂoccosum (7), Trichophyton
violaceum (4), Microsporum gypseum (3), Trichophyton
tonsurance (2), Trichophyton verrucosum (2), Trichophy-
ton schoenlineii (1) and unknown dermatophyte (1). There
was no resistance isolates to clotrimazole and miconazole
and the other antifungal drugs reveals different ranges of
resistance on dermatophyte isolates. Fluconazole had poor
effects on the isolates.
Conclusion: This study reveals that clotrimazole,
terbinaﬁne, miconazole and griseofulvin were the best
antifungal agents in treatment of dermatophytosis. Disk
diffusion method is a simple and valuable method for
dermatophyte susceptibility testing and could be uses for
evaluation of dermatophyte resistance in routine medical
laboratories.
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Background: Clinical trials have suggested infusion-
related reactions (IRR) may occur at a higher rate with
Amphotericin B Cholesteryl Sulfate Complex for Injection
(AMPHOTEC) vs. other forms of amphotericin B. However,
these trials did not permit the use of pre-medications
upfront, which are now commonly used. This observational
study was undertaken to describe use of pre-medications
and determine the rate of IRR in the real-world setting.
Methods: The Patient Registry of AMPHOTEC Clinical
Tolerability (PRoACT) is a multi-center, worldwide obser-
vational registry capturing real-world data about current
pre-medication practices and incidence of IRR in patients
receiving AMPHOTEC therapy. Patients beginning treatment
with AMPHOTEC were eligible for enrollment, and were
treated according to their site’s standard treatment prac-
tice. Incidence of IRR was collected during the ﬁrst 10 days
of AMPHOTEC therapy. Additional labs (serum creatinine,
liver function tests) were collected up to 12 wks after treat-
ment start and at drug discontinuation.
Results: From November 1, 2006 to December 31,
2007, 180 hospitalized adult and pediatric patients from
20 world-wide sites were enrolled in PRoACT. Evalu-
able data on 170 patients from 18 sites are available
and reported here (median age 37 yrs [range 0—72];
51.8% male; 21.8% Asian; 78.2% white). There were
a total of 1230 AMPHOTEC infusions (mean/median
[range] dose 167mg/150mg [15—580mg]). Most infusions
(90%; 1105/1230) had pre-medications. Common pre-
medications included: dexamethasone, methylprednisone,
acetaminophen. The IRR rate was 12% (147/1230). The most
common IRR were chills (n = 85), fever (n = 86) and rigors
(n = 65); most (86%) were low severity (Common Toxicity Cri-
teria stage 1 or 2). Other IRR occurred in < 1.1% of injections.
Pre-treatment was associated with decreased odds for IRR
(OR: 0.41, p < .002 [Chi square]).
Conclusions: These data suggest a low rate of IRR with
AMPHOTEC; pre-treatment is associated with decreased IRR
incidence.
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